CORRIGENDUM: Impact of OATP1B1, MDR1 and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects (Clinical Pharmacology & Therapeutics (2013), 93, 3, 275–282, 10.1038/clpt.2012.261);Impact of OATP1B1, MDR1, and CYP3A4 Expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 3, 2013, Pages 275-282

  Ulvestad, M ^a,b   Skottheim, I B ^a   Jakobsen, G S ^c   Bremer, S ^d   Molden, E ^a   Asberg A ^a   Hjelmesaeth J ^c   Andersson, T B ^b   Sandbu, R ^c   Christensen, H ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b ASTRAZENECA R AND D   (Sweden)

^c VESTFOLD HOSPITAL TRUST   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYTOCHROME P450 3A4; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; DRUG CLEARANCE; DUODENUM; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; ILEUM; JEJUNUM; LIVER; MALE; OBESITY; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE;

EID: 84874190918     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/CPT.70     Document Type: Erratum

References (50)

1. Guengerich, F.P. Characterization of human microsomal cytochrome P-450 enzymes. Annu. Rev. Pharmacol. Toxicol. 29, 241-264 (1989
2. International Transporter Consortium et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236 (2010
3. Guengerich, F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39, 1-17 (1999
4. Paine, M.F., Hart, H.L., Ludington, S.S., Haining, R.L., Rettie, A.E. & Zeldin, D.C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos. 34, 880-886 (2006
5. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. & Guengerich, F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994
6. Wacher, V.J., Wu, C.Y. & Benet, L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13, 129-134 (1995
7. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I. & Willingham, M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84, 7735-7738 (1987
8. Abe, T. et al. Identification of a novel gene family encoding human liverspecific organic anion transporter LST-1. J. Biol. Chem. 274, 17159-17163 (1999
9. Hsiang, B. et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274, 37161-37168 (1999
10. Maeda, K. et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin. Pharmacol. Ther. 79, 427-439 (2006
11. Nakagomi-Hagihara, R. et al. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab. Dispos. 34, 862-869 (2006
12. Ho, R.H. et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130,1793-1806 (2006
13. Lin, Y.S. et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 62, 162-172 (2002
14. Lown, K.S. et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62, 248-260 (1997
15. Mouly, S. & Paine, M.F. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm. Res. 20, 1595-1599 (2003
16. Paine, M.F. et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283, 1552-1562 (1997
17. Schuetz, E.G., Furuya, K.N. & Schuetz, J.D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther. 275, 1011-1018 (1995
18. von Richter, O., Burk, O., Fromm, M.F., Thon, K.P., Eichelbaum, M. & Kivistö, K.T. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens. Clin. Pharmacol. Ther. 75, 172-183 (2004
19. Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34, 83-448 (2002
20. Christensen, H. & Hermann, M. Immunological response as a source to variability in drug metabolism and transport. Front. Pharmacol. 3, 8 (2012
21. Hoffmeyer, S. et al. Functional polymorphisms of the human multidrugresistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 97, 3473-3478 (2000
22. Ieiri, I. et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 82, 541-547 (2007
23. Niemi, M. et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14, 429-440 (2004
24. Hedman, M. et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br. J. Clin. Pharmacol. 61, 706-715 (2006
25. Pasanen, M.K., Fredrikson, H., Neuvonen, P.J. & Niemi, M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 82, 726-733 (2007
26. Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M. & Chiba, K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1.5, SLCO1B1.15 and SLCO1B1.15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15, 513-522 (2005
27. Kantola, T., Kivistö, K.T. & Neuvonen, P.J. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther. 64, 58-65 (1998
28. Kearney, A.S., Crawford, L.F., Mehta, S.C. & Radebaugh, G.W. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm. Res. 10, 1461-1465 (1993
29. Lennernäs, H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 42, 1141-1160 (2003
30. Wu, X., Whitfield, L.R. & Stewart, B.H. Atorvastatin transport in the Caco-2 cell model: Contributions of P-glycoprotein and the proton- monocarboxylic acid co-transporter. Pharm. Res. 17, 209-215 (2000
31. Hermann, M., Asberg, A., Christensen, H., Holdaas, H., Hartmann, A. & Reubsaet, J.L. Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin. Pharmacol. Ther. 76, 388-391 (2004
32. Lilja, J.J., Kivistö, K.T. & Neuvonen, P.J. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin. Pharmacol. Ther. 66, 118-127 (1999
33. Amundsen, R., Christensen, H., Zabihyan, B. & Asberg, A. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab. Dispos. 38, 1499-1504 (2010
34. Chen, C. et al. Differential interaction of 3-hydroxy-3-methylglutaryl- coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab. Dispos. 33, 537-546 (2005
35. Jacobsen, W. et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Dispos. 28, 1369-1378 (2000
36. Tirona, R.G., Leake, B.F., Merino, G. & Kim, R.B. Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276, 35669-35675 (2001
37. Skottheim, I.B., Gedde-Dahl, A., Hejazifar, S., Hoel, K. & Asberg, A. Statin induced myotoxicity: The lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur. J. Pharm. Sci. 33, 317-325 (2008
38. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ. Tech. Rep. Ser. 894, i-xii, 1-253 (2000
39. Barness, L.A., Opitz, J.M. & Gilbert-Barness, E. Obesity: genetic, molecular, and environmental aspects. Am. J. Med. Genet. A 143A, 3016-3034 (2007
40. Cheng, P.Y. & Morgan, E.T. Hepatic cytochrome P450 regulation in disease states. Curr. Drug Metab. 2, 165-183 (2001
41. Greenblatt, D.J., Abernethy, D.R., Locniskar, A., Harmatz, J.S., Limjuco, R.A. & Shader, R.I. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61, 27-35 (1984
42. Berggren, S. et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol. Pharm. 4, 252-257 (2007
43. Canaparo, R. et al. Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples. Basic Clin. Pharmacol. Toxicol. 100, 240-248 (2007
44. Bruyere, A. et al. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Mol. Pharm. 7, 1596-1607 (2010
45. de Waziers, I., Cugnenc, P.H., Yang, C.S., Leroux, J.P. & Beaune, P.H. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253, 387-394 (1990
46. Kolars, J.C. et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 4, 247-259 (1994
47. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254 (1976
48. Bremer, S., Rootwelt, H. & Bergan, S. Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells. Clin. Chem. 53, 1023-1029 (2007
49. Ulvestad, M., Björquist, P., Molden, E., Asberg, A. & Andersson, T.B. OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture. Biochem. Pharmacol. 82, 1219-1226 (2011
50. Darwich, A.S., Neuhoff, S., Jamei, M. & Rostami-Hodjegan, A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: A simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr. Drug Metab. 11, 716-729 (2010